Literature DB >> 2268736

Biomechanical effects of the full range of useful doses of (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) on femur diaphyses and cortical bone tissue in rats.

J L Ferretti1, G Cointry, R Capozza, E Montuori, E Roldán, A Pérez Lloret.   

Abstract

The effects of i.p. doses of 0.016, 0.16, 1.6, 5, 16, 50 and 160 microM/kg/day of APD, over a period of 23 days, on geometric and biomechanical properties of femoral diaphyses in bending were determined in groups of seven growing rats. Both elastic and ultimate strength increased with low doses and decreased with high doses. Geometric (mass) variables (diaphyseal volume, wall/lumen ratio) correlated positively, and material properties (limit elastic stress, modulus of elasticity) negatively, with log dose. Normal mass and improved quality at low doses, and improved mass and impaired quality data at high doses were obtained. No changes in sectional moment of inertia (Ix, an expression of bone architecture) were observed. Biphasic changes in diaphyseal strength expressed the effects of APD on material quality in spite of mass variation. The contrasting lack of changes in Ix may have reflected the blocking effect of APD on osteoclast-osteoblast communication, essential for directional modulation of remodelling.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2268736     DOI: 10.1016/0169-6009(90)90020-g

Source DB:  PubMed          Journal:  Bone Miner        ISSN: 0169-6009


  10 in total

1.  The beneficial effect of Radix Dipsaci total saponins on bone metabolism in vitro and in vivo and the possible mechanisms of action.

Authors:  Y B Niu; Y H Li; X H Kong; R Zhang; Y Sun; Q Li; C Li; L Liu; J Wang; Q B Mei
Journal:  Osteoporos Int       Date:  2012-04-26       Impact factor: 4.507

Review 2.  Adverse effects of bisphosphonates. A comparative review.

Authors:  S Adami; N Zamberlan
Journal:  Drug Saf       Date:  1996-03       Impact factor: 5.606

3.  Site-dependent bone mineral density response to oral pamidronate and calcium in postmenopausal osteoporosis: a preliminary report.

Authors:  J C Barreira; O D Messina; J A Maldonado-Cocco; E J Roldan
Journal:  Clin Rheumatol       Date:  1997-06       Impact factor: 2.980

4.  Role of oral pamidronate in preventing bone loss in postmenopausal women.

Authors:  B Lees; S W Garland; C Walton; D Ross; M I Whitehead; J C Stevenson
Journal:  Osteoporos Int       Date:  1996       Impact factor: 4.507

Review 5.  Bisphosphonates in osteoporosis?

Authors:  O L Bijvoet; R Valkema; C W Löwik; S E Papapoulos
Journal:  Osteoporos Int       Date:  1993       Impact factor: 4.507

Review 6.  New bisphosphonates in osteoporosis.

Authors:  H Fleisch
Journal:  Osteoporos Int       Date:  1993       Impact factor: 4.507

7.  Recovery from pamidronate (APD): a two-year study in the dog.

Authors:  M D Grynpas; M Kasra; M Dumitriu; R Nespeca; J M Very; B P Mertz
Journal:  Calcif Tissue Int       Date:  1994-10       Impact factor: 4.333

8.  Effect of ibandronate on bending strength and toughness of rodent cortical bone: Possible implications for fracture prevention.

Authors:  T Savaridas; R J Wallace; S Dawson; A H R W Simpson
Journal:  Bone Joint Res       Date:  2015-06       Impact factor: 5.853

9.  Chlorogenic Acid Prevents Osteoporosis by Shp2/PI3K/Akt Pathway in Ovariectomized Rats.

Authors:  Rong Ping Zhou; Si Jian Lin; Wen Bing Wan; Hui Ling Zuo; Fen Fen Yao; Hui Bing Ruan; Jin Xu; Wei Song; Yi Cheng Zhou; Shi Yao Wen; Jiang Hua Dai; Mei Lan Zhu; Jun Luo
Journal:  PLoS One       Date:  2016-12-29       Impact factor: 3.240

10.  Analysis of anti-osteoporosis function of chlorogenic acid by gene microarray profiling in ovariectomy rat model.

Authors:  Jun Min; Zhen Yuan; Qiao Zhang; Sijian Lin; Kai Wang; Jun Luo
Journal:  Biosci Rep       Date:  2018-08-31       Impact factor: 3.840

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.